Brolucizumab is noninferior to aflibercept and requires less-frequent injections for patients with neovascular age-related macular degeneration (nAMD), according to results from two phase-3 trials. Earlier this month, Novartis announced that the U.S. Food and Drug Administration accepted the company’s brolucizumab application for the treatment of nAMD. Reductions in central subfield thickness (CST) on optical coherence tomography (OCT) from baseline to week 16 and to week 48 were significantly greater with brolucizumab than with aflibercept in both trials. (Click here to read the rest of the article)
Preclinical Ophthalmic Contract Research